PT  - JOURNAL ARTICLE
AU  - Roe, Matthew T.
AU  - Moliterno, David J.
TI  - The EPILOG Trial
DP  - 1998 May 01
TA  - Cleveland Clinic Journal of Medicine
PG  - 267--272
VI  - 65
IP  - 5
4099  - http://www.ccjm.org/content/65/5/267.short
4100  - http://www.ccjm.org/content/65/5/267.full
SO  - Cleve Clin J Med1998 May 01; 65
AB  - The EPILOG trial showed that the platelet glycoprotein llb/llla inhibitor abciximab, together w i t h heparin in a low, w e i g h t -adjusted dose, markedly reduced the risk of acute ischemic complications during percutaneous coronary revascularization, w i t h o u t increasing the risk of hemorrhage.